Retractable Technologies introduces novel safety blood collection device

Retractable Technologies, Inc. (NYSE MKT: RVP) announced today the launch of a new innovative product, the VanishPoint® Blood Collection Set (BCS).

The VanishPoint® BCS is a novel safety blood collection device for diagnostic purposes that provides the ease of a shorter blood collection needle with preattached tubing. The unique design has integrated finger grips allowing for handling ease without the need for wings, which can interfere with disposal. The automated needle retraction is activated by depressing a retraction trigger located near the finger grip area, allowing for easy one-handed activation, without changes in hand position, while reducing the risk of inadvertent activation. In addition, the needle retraction automatically clamps the tubing, reducing the risk of exposure to blood.

The VanishPoint® BCS features automated, in-vein activation, which virtually eliminates exposure to the contaminated needle, effectively reducing the risk of needlestick injuries and preventing reuse. The wingless design allows for easy disposal. The VanishPoint® BCS contains no natural rubber latex, no DEHP, and no PVC. The kink-resistant tubing is available in 7" and 12" lengths. This new product is available in a variety of needle gauges. The trigger indicator is color coded to indicate needle gauge. The clear body of the device allows for flashback visualization.

Studies have shown that superior needlestick prevention is achieved by safety devices with automated safety features, as opposed to devices with manually activated safety features. All VanishPoint® safety devices feature in-patient, automated safety designs to minimize exposure to contaminated needles and reduce the risk of needlestick injuries.

Source:

Retractable Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Long COVID linked to persistence of SARS-CoV-2 spike protein in blood